Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.

@article{vanErp2009PharmacogeneticPA,
  title={Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.},
  author={Nielka P. van Erp and Karel Eechoute and Astrid A M van der Veldt and John B.A.G. Haanen and An K. L. Reyners and Ron H. J. Mathijssen and Epie Boven and Tahar van der Straaten and Ren{\'e}e F. Baak-Pablo and Judith A. M. Wessels and H. J. Guchelaar and Hans J Gelderblom},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 26},
  pages={
          4406-12
        }
}
  • N. V. van ErpK. Eechoute H. Gelderblom
  • Published 10 September 2009
  • Biology, Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To identify genetic markers in the pharmacokinetic and pharmacodynamic pathways of sunitinib that predispose for development of toxicities: thrombocytopenia, leukopenia, mucosal inflammation, hand-foot syndrome, and any toxicity according to National Cancer Institute Common Toxicity Criteria higher than grade 2. PATIENTS AND METHODS A multicenter pharmacogenetic association study was performed in 219 patients treated with single-agent sunitinib. A total of 31 single nucleotide… 

Tables from this paper

CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma.

Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors

The need for dose reduction and cessation of therapy was tested for an association with single nucleotide polymorphisms (SNPs) in genes related to imatinib pharmacology and results may help identifying patients at increased risk for toxicity who could benefit from intensified follow-up.

Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma

It is shown that polymorphisms in IL8 rs1126647 and IL13 rs1800925 are associated with sunitinib-induced toxicities.

Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib

It is shown that polymorphisms in the pharmacokinetic and pharmacodynamic pathways of sunitinib are associated with survival in GIST, which may help to identify patients that benefit more from treatment with sunit inib.

Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study

Increased cumulated drug exposure and UGT1A9 polymorphism identified patients at high risk for early sorafenib-induced severe toxicity and further PK/PD studies on larger population are warranted to confirm these preliminary results.

ABCG2 rs2231142 polymorphism is related to sunitinib-induced toxicity in metastatic renal cell carcinoma: a systematic review

It was suggested that rs2231142 was associated with sunitinib-induced toxicity in metastatic renal cell carcinoma and any hematologic toxicity > grade 2 (n=1), however, such connection was not observed in some articles about thrombocytopenia, neutropenia or hand-foot syndrome.

Effects of single nucleotide polymorphisms on treatment outcomes and toxicity in patients treated with sunitinib.

Certain SNPs of KDR may affect treatment outcome and toxicity in patients treated with sunitinib.

Genetic Polymorphisms Associated with a Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Cancer Treated with Sunitinib

Genetic polymorphisms in three genes involved in sunitinib pharmacokinetics are associated with PFS in mRCC patients treated with this drug, and the findings advocate prospective validation and further elucidation of these genetic determinants in relation to sunit inib exposure and efficacy.

Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination.

The results revealed the importance of SLCO1B3 and NR1I2 in the sensitivity to carboplatin/paclitaxel thrombocytopenia.

Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.

The ABCG2 -15622C/T polymorphism and ABCG1/T haplotype resulted in a gefitinib-dependent, moderate-to-severe diarrhea suggesting that these pharmacogenetic markers should be considered to optimize NSCLC treatment.
...

References

SHOWING 1-10 OF 41 REFERENCES

Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.

  • C. RudinWanqing Liu M. Ratain
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
A combined pharmacogenomic and pharmacokinetic model helps to define and differentiate the primary determinants of skin and gastrointestinal toxicity of erlotinib.

Irinotecan pathway genotype analysis to predict pharmacokinetics.

  • R. MathijssenS. Marsh H. McLeod
  • Biology, Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2003
It is concluded that genotyping for ABCB1 1236C>T may be one of the factors assisting with dose optimization of irinotecan chemotherapy in cancer patients and additional investigation is required to confirm these findings in a larger population.

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.

Virtually all of the side effects associated with these agents can be managed effectively in the majority of patients with medical treatment or supportive interventions.

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

  • S. FaivreC. Delbaldo E. Raymond
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
Antitumor activity supports further studies in patients with renal cell carcinoma, gastrointestinal, neuroendocrine, and stromal tumors and indicates that potentially active target plasma concentrations > or = 50 ng/mL can be achieved with moderate interpatient variability and a long half-life compatible with a single daily dosing.

Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics.

Genetic variability in PXR and CAR genetic variants and alternatively spliced mRNAs may ultimately allow predictions of interindividual differences in target gene induction and drug-drug interactions.

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

At steady state, imatinib is insensitive to potent CYP3A4 inhibition and relies on alternate elimination pathways and interaction studies that are done after a single dose may not be applicable when drugs are administered chronically.

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

The relevance of a dose re-escalation with sunitinib to achieve maximal patient benefit and treatment outcome with this potent yet sometimes challenging drug is illustrated.

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa.